Compare SG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SG | ARVN |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 658.2M |
| IPO Year | 2021 | 2018 |
| Metric | SG | ARVN |
|---|---|---|
| Price | $7.00 | $10.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 19 |
| Target Price | $8.43 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 3.6M | 640.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | N/A |
| Revenue | ★ $679,474,000.00 | $262,600,000.00 |
| Revenue This Year | $7.60 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $4.49 | $5.90 |
| 52 Week High | $17.27 | $14.22 |
| Indicator | SG | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 40.77 |
| Support Level | $6.51 | $9.96 |
| Resistance Level | $7.43 | $10.18 |
| Average True Range (ATR) | 0.41 | 0.55 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 57.80 | 23.95 |
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.